A coronavirus vaccine being developed by U.S. pharmaceutical company Pfizer Inc. is “more than 90 percent effective” in preventing COVID-19, the company said Monday after an initial analysis of data from a large study.
The data comes from the analysis of 94 confirmed COVID-19 cases in a Phase III study with 43,538 participants, according to a Pfizer press release.
Pfizer, which is collaborating with the German biotechnology company BioNTech SE in the development of the vaccine, said that no serious safety concerns have been observed so far.
The companies expect to apply for an Emergency Use Authorization (EUA) for the vaccine from the U.S. Food and Drug Administration during November.
“Today is a great day for science and mankind,” Pfizer Chairman Albert Bourla said in a statement on Monday.
“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most as infection rates reach new records, hospitals fail due to overcapacity and economies struggle to reopen.
This is a development report that will be updated as more information becomes available.